Summary of Ventyx Biosciences Conference Call Company Overview - Ventyx Biosciences, founded in 2021, initially focused on immunology but has expanded to neuro, immunology, cardiovascular, and metabolic areas. [3][4] - The company has pivoted to focus on inflammasome research, particularly NLRP3 inhibitors, after initial compounds did not meet competitive endpoints in Crohn's and psoriasis. [3][4] Key Developments and Products - Ventyx is developing several compounds, including CNS penetrant compound 3232, which has shown promising biomarker changes in cardiometabolic obesity patients. [6][7] - The trial for 3232 demonstrated significant brain penetration and aimed to assess CNS-mediated control of obesity, although it was concluded that NLRP3 does not affect weight loss. [6][8] - The company is also working on peripheral compound 2735 for recurrent pericarditis (RP), with an upcoming data readout expected in Q4. [18][19] Clinical Insights - The 3232 trial showed strong effects on NLRP3 markers and inflammation, with a notable reduction in CRP levels, indicating potential cardiovascular applications. [9][10] - The company is exploring the relationship between neuroinflammation and neurodegenerative diseases, with interest from partners in conditions like Parkinson's and Alzheimer's. [11][12] - For the RP trial with compound 2735, success is defined by a significant reduction in pain scores and CRP levels, aiming for a competitive edge against existing treatments. [18][20] Market Position and Strategy - Ventyx aims to position its drugs as add-ons to existing therapies, addressing systemic low-grade inflammation linked to various diseases. [13][14] - The company is cautious about pursuing neurodegenerative trials independently due to their complexity and unproven biology. [11][12] - The Rofan partnership with Sanofi is focused on 3232, with ongoing negotiations and data sharing expected. [15][17] Future Outlook - The timeline for moving from phase two to phase three trials is estimated to be between six to nine months, with plans to expand into other countries. [35][36] - The company emphasizes the importance of safety in its compounds, having conducted extensive testing without significant safety signals. [34][35] - Ventyx expresses optimism about the potential for multiple drugs in the inflammasome space, highlighting the excitement surrounding ongoing research and development. [37]

Key Takeaways The phase II study showed VTX3232 was safe and well-tolerated as monotherapy and with Wegovy.VTYX reported major hsCRP and IL-6 reductions plus improvements in key inflammatory biomarkers.Combination therapy with Wegovy cut inflammation further but did not enhance weight-loss outcomes.Shares of Ventyx Biosciences (VTYX) have skyrocketed 156% in the past month. The massive surge in the stock price was primarily driven by the success of the company’s mid-stage study evaluating its investigationa ...

SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference in London. Jefferies Global Healthcare Conference details:Fireside ChatDate: Wednesday, Novembe ...

SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference in London. Jefferies Global Healthcare Conference details:Fireside ChatDate: Wednesday, Novembe ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40928 Ventyx Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-2996852 (St ...

Exhibit 99.1 Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress SAN DIEGO, CA, November 6, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported third quarter financial results and highlighted recent pipeline and business progress. "I am prou ...

Data from the recent Phase 2 study position Ventyx’s NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a biomarker trial support the potential use of VTX3232 as a disease-modifying therapy for patients with Parkinson’s diseaseTopline data from Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025Cash, cash equivalents and marketable securities balance of $192.6M as of September 30, 2025, e ...

Core Insights - The biotech sector is experiencing significant momentum, with many clinical-stage and commercial biopharma stocks reaching new 52-week highs due to breakthrough trial data, strategic deals, and earnings surprises [1] Company Summaries - **Metsera Inc. (MTSR)**: A clinical-stage biopharmaceutical company focused on developing hormone analog peptides for obesity and related metabolic diseases. Recently, Novo Nordisk made a $9 billion unsolicited acquisition proposal, which Metsera's board considers superior to its existing agreement with Pfizer [2][3]. Metsera announced positive Phase 2b results for its GLP-1 receptor agonist MET-097i, showing up to 14.1% weight loss after 28 weeks, supporting Phase 3 initiation in late 2025 [4]. The stock rose from $32.35 to a 52-week high of $66.10, a gain of 104.3% [5]. - **Indivior Plc (INDV)**: Develops buprenorphine-based therapies for opioid dependence. The company reported Q3 net income of $42 million, up from $22 million a year ago, with adjusted earnings of $93 million, exceeding Wall Street's expectations [6][7]. The stock increased from $20.86 to a 52-week high of $30.55, reflecting a 46.5% gain [7]. - **Insmed Inc. (INSM)**: Focused on therapies for serious and rare diseases, Insmed reported a Q3 net loss of $370 million but saw net product revenue rise to $142.3 million from $93.4 million last year [8][9]. The company raised its full-year 2025 revenue guidance for ARIKAYCE to $420 million - $430 million, indicating 15% - 18% growth year-over-year [10]. The stock surged from $76.54 to a 52-week high of $194.70, marking a 154.4% gain [10]. - **Ventyx Biosciences Inc. (VTYX)**: A clinical-stage biotech company developing therapies for autoimmune and neurodegenerative diseases. Ventyx reported positive Phase 2 results for its NLRP3 inhibitor VTX3232, showing strong safety and tolerability [11][13]. The stock rose from $3.01 to a 52-week high of $8.52, a gain of over 183% [14]. - **Inhibrx Biosciences Inc. (INBX)**: Focuses on oncology and rare diseases, announcing positive topline results from its ChonDRAgon study for ozekibart in chondrosarcoma [15]. The stock increased from $18.35 to a 52-week high of $83.78, representing a gain of 356.6% [16]. - **ABIVAX Société Anonyme (ABVX)**: Developing therapies for chronic inflammatory diseases, ABIVAX presented positive Phase 3 data for obefazimod in ulcerative colitis [17]. The stock rose from $7.83 to an all-time high of $106.73, marking a significant gain of 1263% [18]. - **Arrowhead Pharmaceuticals Inc. (ARWR)**: Developing RNAi-based therapies, Arrowhead finalized a licensing agreement with Novartis for ARO-SNCA, with financial terms including a $200 million upfront payment [19][20][21]. The stock increased from $29.70 to a 52-week high of $43.33, representing a gain of over 45% [21]. - **Kodiak Sciences Inc. (KOD)**: Focused on retinal diseases, Kodiak announced positive Phase 1b data for KSI-101, showing significant vision improvements [22][23][24]. The stock climbed from $8.98 to a 52-week high of $21.17, delivering a 135.7% gain [22]. - **Arcutis Biotherapeutics Inc. (ARQT)**: Focused on dermatological treatments, Arcutis reported Q3 net income of $7.4 million, a turnaround from a net loss last year, with revenue up 122% year-over-year [25][26]. The stock rose from $14.99 to a 52-week high of $27.08, representing a gain of over 80% [27]. - **Maze Therapeutics Inc. (MAZE)**: Developing precision therapies for various diseases, Maze announced positive Phase 1 results for MZE782 and secured $150 million in a private placement [28][29]. The stock rose from $11.21 to a new 52-week high of $34.29, returning a gain of 206% [29]. - **Supernus Pharmaceuticals Inc. (SUPN)**: Focused on CNS disorders, Supernus is expected to report Q3 earnings of $0.82 per share and revenue of $180.22 million [30][31]. The stock increased from $38.21 to a 52-week high of $57.65, representing a gain of over 50% [31].

Ventyx Biosciences Inc. (NASDAQ:VTYX) is one of the best NASDAQ stocks under $5 to buy now. On October 22, Ventyx Biosciences announced positive topline results from its Phase 2 study of the oral, once-daily drug VTX3232 in 175 participants with obesity and cardiovascular risk factors. The study was a randomized, double-blind, placebo-controlled, multicenter trial that evaluated VTX3232 versus placebo, alone or combined with semaglutide. The primary goal was safety and tolerability, and the secondary endp ...

Group 1 - The VTX3232 results press release is now available on the company's website, indicating a focus on transparency and accessibility of information [2] - Slides presented during the call will be available on the webcast and subsequently posted on the company's website, emphasizing the company's commitment to providing detailed information to stakeholders [2] Group 2 - The call includes forward-looking statements under the Safe Harbor Act, highlighting the company's proactive approach to communicate potential future developments while acknowledging associated risks and uncertainties [3]